Interdisciplinary Research from F1000

These papers were selected from multiple disciplines from the Faculty of 1000, a Web-based literature awareness tool http://www.facultyof1000.com.L.T. Vassilev et al., "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2," Science, 303:844–8, Feb. 6, 2004.This paper is important because it challenges the conventional wisdom that protein-protein interactions are poor drug targets. p53 ... is inhibited when bound by MDM2. ... It is possible to disrupt the p53-MDM2 int

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

These papers were selected from multiple disciplines from the Faculty of 1000, a Web-based literature awareness tool http://www.facultyof1000.com.

L.T. Vassilev et al., "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2," Science, 303:844–8, Feb. 6, 2004.

This paper is important because it challenges the conventional wisdom that protein-protein interactions are poor drug targets. p53 ... is inhibited when bound by MDM2. ... It is possible to disrupt the p53-MDM2 interaction in cells with a small organic molecule at low micromolar concentrations.

- William Kaelin, Harvard Medical School

W.C. Winkler et al., "Control of gene expression by a natural metabolite-responsive ribozyme," Nature, 428:281–6, March 18, 2004.

The authors report that glucosamine-6-phosphate (GlcN6P) activates a ribozyme embedded within the 5' untranslated region of the gene encoding its synthesis. This ribozyme cleaves the messenger RNA, thereby suppressing GlcN6P production. ... It will be interesting to see if riboswitches that are ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies